These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2401 related articles for article (PubMed ID: 26961085)

  • 1. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.
    Mandl SJ; Rountree RB; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Dirmeier U; Steigerwald R; Giffon T; Laus R; Delcayre A
    Cancer Immunol Immunother; 2012 Jan; 61(1):19-29. PubMed ID: 21822917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
    Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
    Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
    Foy SP; Sennino B; dela Cruz T; Cote JJ; Gordon EJ; Kemp F; Xavier V; Franzusoff A; Rountree RB; Mandl SJ
    PLoS One; 2016; 11(2):e0150084. PubMed ID: 26910562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.
    Fend L; Gatard-Scheikl T; Kintz J; Gantzer M; Schaedler E; Rittner K; Cochin S; Fournel S; Préville X
    Cancer Immunol Res; 2014 Dec; 2(12):1163-74. PubMed ID: 25168392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
    Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
    J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
    Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
    Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
    Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
    Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 121.